Oxaliplatin liposomal - Regulon

Drug Profile

Oxaliplatin liposomal - Regulon

Alternative Names: Lipoxal

Latest Information Update: 16 Dec 2015

Price : $50

At a glance

  • Originator Regulon
  • Class Antineoplastics; Platinum complexes; Small molecules
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glioma
  • No development reported Colorectal cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 29 Dec 2014 Phase II development is ongoing
  • 08 Dec 2014 Cisplatin lipososmal licensed to In Ovations Holdings
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top